Anavex Life Sciences Corp (AVXL)

[sokol]

My speculation is that we made the low for 2018. The low of $2.65 for 2018, so far, is the lowest the AVXL share price has been since September of 2016 when it bottomed at $2.43 - $2.45 in September of 2016. However, despite what some on this board may dispute, the company has made progress since 2016. It certainly raised more funds and has uncovered more options for the potential uses and approval of AVXL 2-73. Although there has been a delay, it is likely to move forward with the 3 clinical trials at some point early this year. Furthermore, the indicators I have available to me, although not perfect, suggest that the selling/move down is exhausted for the time being. Therefore, my best guess, do your own DD, is that we are more likely due for a price move up in the near future. There is no point in Dr. M appearing at the Noble conference Monday, January 29, unless he has something to say. After all, the subject is whether there is a cure for AD on the horizon. I do not expect him to say anything definitive, but he certainly cannot say NO there is no hope for a cure or for treating AD because that has been the main focus of all of his efforts and endeavors over the past several years. Moreover, he has agreed to put himself in the position of having to say something about what the company is doing and will do in regard to its AD clinical trial. Let’s wait and see what he has to say next week.